{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:44:17Z","timestamp":1771659857393,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG075335"],"award-info":[{"award-number":["R01AG075335"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ahj.2024.09.004","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T05:49:57Z","timestamp":1726724997000},"page":"161-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Assessing methods to ascertain persistence and adherence of oral anticoagulants in patients with atrial fibrillation"],"prefix":"10.1016","volume":"278","author":[{"given":"Anran","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushama","family":"Kattinakere Sreedhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie C.","family":"Lauffenburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyse","family":"DiCesare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kueiyu Joshua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.09.004_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21090","article-title":"Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis","volume":"21","author":"Sterne","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ahj.2024.09.004_bib0002","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left Atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA plavix feasibility study with watchman left atrial appendage closure technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.09.004_bib0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/STROKEAHA.107.496554","article-title":"Barriers to anticoagulation in patients with atrial fibrillation - changing physician-related factors","volume":"39","author":"Lane","year":"2008","journal-title":"Stroke (1970)"},{"key":"10.1016\/j.ahj.2024.09.004_bib0004","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2024.09.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011427","article-title":"Trajectories of oral anticoagulation adherence among medicare beneficiaries newly diagnosed with atrial fibrillation","volume":"8","author":"Hernandez","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2024.09.004_bib0006","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.09.004_bib0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.09.004_bib0008","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.004","article-title":"Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents","volume":"27","author":"Rose","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.ahj.2024.09.004_bib0009","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke (1970)"},{"key":"10.1016\/j.ahj.2024.09.004_bib0010","first-page":"157","article-title":"Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","author":"Graham","year":"2015","journal-title":"Circulation (New York, NY)"},{"key":"10.1016\/j.ahj.2024.09.004_bib0011","first-page":"1192","article-title":"Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study","volume":"76","author":"Xian","year":"2019","journal-title":"Arch Neurol (Chicago)"},{"key":"10.1016\/j.ahj.2024.09.004_bib0012","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/phar.1989","article-title":"Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation","volume":"37","author":"Manzoor","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ahj.2024.09.004_bib0013","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1055\/a-1508-8187","article-title":"Using a simple prescription gap to determine warfarin discontinuation can lead to substantial misclassification","volume":"122","author":"Lin","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.09.004_bib0014","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/jth.15415","article-title":"Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: results from the GARFIELD-AF registry","volume":"19","author":"Cools","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.09.004_bib0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCOUTCOMES.110.937680","article-title":"Warfarin discontinuation after starting warfarin for atrial fibrillation","volume":"3","author":"Fang","year":"2010","journal-title":"Circ Cardiovas Qual Outcomes"},{"key":"10.1016\/j.ahj.2024.09.004_bib0016","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.amjmed.2018.12.023","article-title":"Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation","volume":"132","author":"Graham","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2024.09.004_bib0017","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1161\/STROKEAHA.117.017474","article-title":"Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack","volume":"48","author":"Coleman","year":"2017","journal-title":"Stroke (1970)"},{"key":"10.1016\/j.ahj.2024.09.004_bib0018","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ageing\/afab024","article-title":"Reasons for discontinuing oral anticoagulation therapy for atrial fibrillation: a systematic review","volume":"50","author":"Buck","year":"2021","journal-title":"Age and ageing"},{"key":"10.1016\/j.ahj.2024.09.004_bib0019","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.clinthera.2006.09.021","article-title":"Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization","volume":"28","author":"Caetano","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2024.09.004_bib0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11606-016-3972-z","article-title":"Effect of combination therapy on adherence among US patients initiating therapy for hypertension: a cohort study","volume":"32","author":"Lauffenburger","year":"2017","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ahj.2024.09.004_bib0021","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2024.09.004_bib0022","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.09.004_bib0023","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2024.09.004_bib0024","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ahj.2024.09.004_bib0025","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE initiative","volume":"143","author":"Franklin","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.09.004_bib0026","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1038\/s41467-022-32310-3","article-title":"Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ahj.2024.09.004_bib0027","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2006.10.018","article-title":"Comparison of measures of medication persistency using a prescription drug database","volume":"153","author":"Hudson","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.09.004_bib0028","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ahj.2020.04.016","article-title":"Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: results from outcomes registry for better informed treatment of atrial fibrillation II (ORBIT-AF II)","volume":"226","author":"Jackson","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.09.004_bib0029","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.joa.2015.04.004","article-title":"Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: a single-center observational study","volume":"31","author":"Shiga","year":"2015","journal-title":"J Arrhythm"},{"key":"10.1016\/j.ahj.2024.09.004_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1160\/TH15-04-0350","article-title":"Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study","volume":"115","author":"Martinez","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.09.004_bib0031","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2019-315307","article-title":"Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study","volume":"106","author":"Banerjee","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2024.09.004_bib0032","first-page":"245","article-title":"Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation","volume":"12","author":"Song","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ahj.2024.09.004_bib0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40256-016-0171-6","article-title":"A summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation","volume":"16","author":"Obamiro","year":"2016","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:01:08Z","timestamp":1738573268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324002370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":33,"alternative-id":["S0002870324002370"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.09.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing methods to ascertain persistence and adherence of oral anticoagulants in patients with atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}